A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial Profile

A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 06 Dec 2016 Preliminary results (n=37) of the phase 1b portion, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2016 Accrording to an According to an AbbVie media release, preliminary data will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition
    • 04 Dec 2016 Interim results published in an AbbVie Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top